Transgene Receives MHRA Approval for Lead myvac(TM) Individualized Immunotherapy, TG4050, to Commence Clinical Development in HPV Negative Head and Neck Cancers in the UK
Boursorama•10/07/2019 à 17:45
Phase 1 clinical trial, expected to start in H2 2019, will be co-funded by Transgene and its collaboration partner NEC
Strasbourg, France, July 10, 2019, 5:45 p.m. CET - Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of solid tumors, today announces it has received the approval from the UK Medicines and Healthcare Products Regulatory Agency (MHRA) to proceed with a Phase 1 clinical trial of its lead myvac(TM) candidate TG4050. TG4050 is being developed as a potential treatment for patients with newly diagnosed, locoregionally advanced, HPV negative, squamous cell carcinoma of the head and neck (SCCHN).
TG4050 is an individualized MVA-based immunotherapy derived from the myvac(TM) platform. It has been designed to stimulate and educate the patient's immune system to recognize and destroy tumor cells. Tumor cells accumulate mutations and each patient has a set of mutations that are unique to their tumor. TG4050 has been designed to target a panel of these patient specific mutations, which have been selected using NEC's Neoantigen Prediction System.